ESR1 and breast cancer: This heterogeneity may be caused by distinct differences in the molecular subtypes of ER+/HER2− BC, including subtypes with varying estrogen and progesterone receptor expression, and those that are immunogenic, proliferative and receptor tyrosine kinase-driven, which require specific treatments3.